; (C) new data tools, techniques, and processes to identify and publicly disclose relevant information concerning illicit drugs containing xylazine, novel synthetic opioids, or other emerging substances of concern; and (D) all other areas determined by the Director to be critical to the development and deployment of technologies to measure and analyze the presence of xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs; (2) support activities to inform and expand the development of near-real time spectrometry capabilities regarding xylazine, novel synthetic opioids, and other emerging compounds in illicit drugs; (3) convene the private sector, institutions of higher education, nonprofit organizations, Federal laboratories, and other Federal agencies engaged in the analysis of illicit drugs to develop coordinated strategies and voluntary best practices for the safe handling, transport, and analysis of illicit drugs containing xylazine, novel synthetic opioids, or other emerging substances of concern; (4) establish or expand collaborative partnerships or consortia with other government agencies engaged in counternarcotic research and development, institutions of higher education, Federal laboratories, and the private sector to enhance narcotic and opioid detection and analysis capabilities regarding xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs